No Data
Kelun Pharmaceutical-B has submitted an IPO prospectus and plans to list on the Hong Kong Stock Exchange, exclusively sponsored by CITIC Securities.
On June 27, 2024, Elpiscience Biopharmaceuticals, Inc. (referred to as "Ke Wang Medicine") from Shanghai submitted a prospectus to the Hong Kong Stock Exchange and plans to go public on the Hong Kong main board. Ke Wang Medicine Prospectus Link: https://www1.hkexnews.hk/app/sehk/2024/106577/documents/sehk24062702244_c.pdf Ke Wang Medicine, established in 2017, is a clinical-stage biopharmaceutical company dedicated to using next-generation therapies to innovate cancer treatments worldwide. With a deep understanding and pioneering research of the tumor microenvironment (TME), it strives to cover innovative and promising targets and pathways in cancer biology with a systematic approach, leading the next wave of innovation in immuno-oncology. Ke Wang Medicine's strategic focus is to eliminate inhibitory factors in the TME, induce higher immune responses across tumor types, and achieve more powerful anti-tumor activity. Global industry leaders (including Ke Wang Medicine's co-founders Drs. Ji Xiaohui and
瑞恩資本Ryanben CapitalJun 28 13:29